264 related articles for article (PubMed ID: 22992199)
21. 3'-18F-fluoro-3'-deoxy-L-thymidine: a new tracer for staging metastatic melanoma?
Cobben DC; Jager PL; Elsinga PH; Maas B; Suurmeijer AJ; Hoekstra HJ
J Nucl Med; 2003 Dec; 44(12):1927-32. PubMed ID: 14660718
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography.
Yap CS; Czernin J; Fishbein MC; Cameron RB; Schiepers C; Phelps ME; Weber WA
Chest; 2006 Feb; 129(2):393-401. PubMed ID: 16478857
[TBL] [Abstract][Full Text] [Related]
23. PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study.
Smyczek-Gargya B; Fersis N; Dittmann H; Vogel U; Reischl G; Machulla HJ; Wallwiener D; Bares R; Dohmen BM
Eur J Nucl Med Mol Imaging; 2004 May; 31(5):720-4. PubMed ID: 14991243
[TBL] [Abstract][Full Text] [Related]
24. 3'-Deoxy-3'-18F-fluorothymidine as a proliferation imaging tracer for diagnosis of lung tumors: comparison with 2-deoxy-2-18f-fluoro-D-glucose.
Yamamoto Y; Nishiyama Y; Ishikawa S; Gotoh M; Bandoh S; Kanaji N; Asakura M; Ohkawa M
J Comput Assist Tomogr; 2008; 32(3):432-7. PubMed ID: 18520552
[TBL] [Abstract][Full Text] [Related]
25. Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT.
Heusch P; Buchbender C; Köhler J; Nensa F; Gauler T; Gomez B; Reis H; Stamatis G; Kühl H; Hartung V; Heusner TA
J Nucl Med; 2014 Mar; 55(3):373-8. PubMed ID: 24504054
[TBL] [Abstract][Full Text] [Related]
26. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG.
Buck AK; Halter G; Schirrmeister H; Kotzerke J; Wurziger I; Glatting G; Mattfeldt T; Neumaier B; Reske SN; Hetzel M
J Nucl Med; 2003 Sep; 44(9):1426-31. PubMed ID: 12960187
[TBL] [Abstract][Full Text] [Related]
27. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic accuracy of (18)F-2-deoxy-fluoro-D-glucose positron emission tomography for pN2 lymph nodes in patients with lung cancer.
Ozawa Y; Hara M; Sakurai K; Nakagawa M; Tamaki T; Nishio M; Shibamoto Y
Acta Radiol; 2010 Mar; 51(2):150-5. PubMed ID: 20092375
[TBL] [Abstract][Full Text] [Related]
29. [18F]FLT-PET and [18F]FDG-PET in the evaluation of radiotherapy for laryngeal cancer.
Been LB; Hoekstra HJ; Suurmeijer AJ; Jager PL; van der Laan BF; Elsinga PH
Oral Oncol; 2009 Dec; 45(12):e211-5. PubMed ID: 19692292
[TBL] [Abstract][Full Text] [Related]
30. 18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI.
Schöder H; Carlson DL; Kraus DH; Stambuk HE; Gönen M; Erdi YE; Yeung HW; Huvos AG; Shah JP; Larson SM; Wong RJ
J Nucl Med; 2006 May; 47(5):755-62. PubMed ID: 16644744
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic accuracy of dual-time-point 18F-FDG PET/CT for the detection of axillary lymph node metastases in breast cancer patients.
Hahn S; Hecktor J; Grabellus F; Hartung V; Pöppel T; Kimmig R; Forsting M; Antoch G; Heusner TA
Acta Radiol; 2012 Jun; 53(5):518-23. PubMed ID: 22547387
[TBL] [Abstract][Full Text] [Related]
32. Utility of ¹⁸F-FDG PET/CT in identifying penile squamous cell carcinoma metastatic lymph nodes.
Rosevear HM; Williams H; Collins M; Lightfoot AJ; Coleman T; Brown JA
Urol Oncol; 2012 Sep; 30(5):723-6. PubMed ID: 21396850
[TBL] [Abstract][Full Text] [Related]
33. Potential impact of 18F-FDG PET/CT on patients selection for neoadjuvant chemotherapy before radical cystectomy.
Rouanne M; Girma A; Neuzillet Y; Vilain D; Radulescu C; Letang N; Yonneau L; Hervé JM; Botto H; Le Stanc E; Lebret T
Eur J Surg Oncol; 2014 Dec; 40(12):1724-30. PubMed ID: 25242381
[TBL] [Abstract][Full Text] [Related]
34. 18F-fluorodeoxyglucose uptake level-based lymph node staging in oropharyngeal squamous cell cancer--role of molecular marker expression on diagnostic outcome.
Sadick M; Weiss C; Piniol R; Frey S; Hoermann K; Schoenberg SO; Sadick H
Oncol Res Treat; 2015; 38(1-2):16-22. PubMed ID: 25633529
[TBL] [Abstract][Full Text] [Related]
35. FDG PET-CT in cervical cancer: relationship between primary tumor FDG uptake and metastatic potential.
Yilmaz M; Adli M; Celen Z; Zincirkeser S; Dirier A
Nucl Med Commun; 2010 Jun; 31(6):526-31. PubMed ID: 20215979
[TBL] [Abstract][Full Text] [Related]
36. Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer.
Everitt SJ; Ball DL; Hicks RJ; Callahan J; Plumridge N; Collins M; Herschtal A; Binns D; Kron T; Schneider M; MacManus M
J Nucl Med; 2014 Jul; 55(7):1069-74. PubMed ID: 24833494
[TBL] [Abstract][Full Text] [Related]
37. Clinical usefulness of dual-time FDG PET-CT in assessment of esophageal squamous cell carcinoma.
Shum WY; Hsieh TC; Yeh JJ; Chen JH; Su CC; Liang JA; Kao CH
Eur J Radiol; 2012 May; 81(5):1024-8. PubMed ID: 21458941
[TBL] [Abstract][Full Text] [Related]
38. The value of 18F-FLT PET for detecting second primary cancers and distant metastases in head and neck cancer patients.
Hoshikawa H; Kishino T; Mori T; Nishiyama Y; Yamamoto Y; Mori N
Clin Nucl Med; 2013 Aug; 38(8):e318-23. PubMed ID: 23455521
[TBL] [Abstract][Full Text] [Related]
39. Impact of FDG-PET/CT imaging on nodal staging for head-and-neck squamous cell carcinoma.
Murakami R; Uozumi H; Hirai T; Nishimura R; Shiraishi S; Ota K; Murakami D; Tomiguchi S; Oya N; Katsuragawa S; Yamashita Y
Int J Radiat Oncol Biol Phys; 2007 Jun; 68(2):377-82. PubMed ID: 17321066
[TBL] [Abstract][Full Text] [Related]
40. Assessment of cervical lymph node metastases using FDG-PET in patients with head and neck cancer.
Yamazaki Y; Saitoh M; Notani K; Tei K; Totsuka Y; Takinami S; Kanegae K; Inubushi M; Tamaki N; Kitagawa Y
Ann Nucl Med; 2008 Apr; 22(3):177-84. PubMed ID: 18498032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]